Farmas USA

buah, genial. GRACIAS!

Esas ARNA VERDES!!!

Malditos trileros de opciones

Pues los 2 bancos más competitivos que he visto son ING y Bankinter, échales un vistazo.
Pero te falta el dato de compra- venta.

el dato compra-venta me da un poco igual, seria para comprar una sola vez si lo hago y punto. no es para operar.

¿Arcelor?, jejeje

Supongo que hablas del Nasdaq? Pues ING creo que no cobra custodia y es competitivo,
pero es Holandés. Bankinter es también competitivo de los que conozco, échales un vistazo.

CTIX +10% por el momento....
La new de ayer creo que era para una buena subida, tras los atques bashers de las ultimas sesiones...

BEVERLY, MA--(Marketwired - August 20, 2015) - Cellceutix Corporation (CTIX) (the "Company"), a clinical stage biopharmaceutical company developing innovative therapies with oncology, dermatology, anti-inflammatory and antibiotic applications, today discussed the Phase 1 clinical trial of Kevetrin in patients with advanced solid tumors. The trial was designed to determine the safety profile of escalating single intravenous doses of Kevetrin. A secondary objective was to assess any preliminary evidence of anti-tumor activity. The trial inclusion limits patients to "Pathologically confirmed solid tumor, locally advanced / metastatic, refractory after standard therapy, or for which no effective curative or surgical treatment options are available."

The trial has accomplished many of its goals and will be concluded shortly. Over 40 patients have been enrolled, providing ample data to confirm the safety of Kevetrin. Kevetrin has been well tolerated and the pharmacokinetic profile was dose dependent and predictable. Importantly, Cellceutix believes that p53 activation has been shown, as measured by p21 expression in peripheral blood samples. To that point, Cellceutix would like to share an excerpt from Company's annual report to the U.S. Food and Drug Administration concerning the Phase 1 trial.

"Of 40 subjects enrolled to date, 31 were evaluable for changes in p21 biomarker (pre-dose and at least 1 time point post-dose blood sample obtained after first dose of Kevetrin). Of the 31 evaluable subjects, 68% had an increase in p21 expression in a range of 3% to 205% and 48% had an increase in p21 expression of ≥ 10%, considered a meaningful increase.
Of the 15 evaluable subjects with gynecological cancers, p21 expression increased in 11 (73%) subjects. Also, p21 expression increased in both of the two subjects with prostate cancer."

These results support the concept that Kevetrin activates p53 by inducing p21 gene expression.​

Framus, échales un vistazo a las NVAX que no me gusta tal como está el mercado.
Ahora la proxima semana rebotan seguro jajaja.